Template for the working groups in the CSF Meeting

Name of the working group: universal access to optimal treatment and diagnostics options and sustainability

Geographical scope: CSF membership

Objective of the working group	Agreement on what the working group members would like to achieve for the given period of time (at most, for this term until the end of 2019): To support the monitoring of the state of universal access to optimal treatment and diagnostics options and their sustainability; to raise awareness to barriers and; make recommendations to national governments, EC, ECDC, WHO and EMA; industry
Sub-objectives	Are there any sub-objectives necessary to describe in order to reach the main objective? 1.Recommend indicators for ECDC/WHO monitoring of progress towards universal access to state of the art medicines and diagnostics 2. Bring out experience from the field on barriers and share experience in using legal tools to challenge IP barriers 3. Identify mechanisms to access cheaper quality medicines and diagnostics to support advocacy of civil society groups at local level
Outputs, Deliverables, Products	 Are there any outputs, deliverables, products the working group aims to come up with? Survey/report on community view (and examples) on legal and commercial barriers to treatment and diagnostics across the three diseases (eg: DAAs, Rifampicin, rifapentin and Truvada) Advocacy calendar of events and opportunity Recommendations for civil society involvement in national and regional negotiation efforts Statement/letters/

Activities	Which activities are identified and agreed upon to reach the objectives? (see table below)	
Timeline	What needs to be done at what point of time to reach the objectives? (see table below)	
Responsibilities	Overall coordination, Who takes over responsibility for which activity (see table below)	

Objective resp. Sub-objective

Activity	Deadline	Responsible	Comments
Ask WHO and ECDC for info for monitoring purposes	16 May Think Tank	Coordination Team	
Advocacy calendar of events and opportunity	On-going	Ann Isabelle	Google doc
Developing a survey on barriers	November	Giorgos,	First draft (include question on stockouts)
Roll out survey	Jan feb		
Analysis and report	May 2019		
Statements, letters, speeches, presentations, posters			(transparency of prices, TRIPS, joint procurements, legal import of generics for personal use)
Round Table on lessons learned on SPCs at AIDS 2018		Richard, Ann Isabelle	

Transparency of pricing

Use of TRIPS Flexibilities

Differential pricing

Legal personal import of generics

Joint procurement mechanisms

Regional government cooperation